Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 18,819	$ 12,365
Short-term investments	249,000	225,459
Accounts receivable, net	2,966	3,607
Inventory	10,352	12,952
Restricted cash	0	25,000
Other current assets	5,214	8,817
Total current assets	286,351	288,200
Property, plant and equipment, net	72,532	70,368
Goodwill	76,501	76,501
Other assets	13,862	6,552
Total assets	449,246	441,621
Current liabilities:
Accounts payable	2,279	2,703
Accrued compensation	12,805	5,749
Accrued clinical trial expenses	11,102	7,708
Other accrued expenses	16,561	6,418
Interest payable	3,167	6,917
Capital lease obligations, current portion	5,883	4,512
Deferred revenue, current portion	20,611	24,473
Senior secured notes, current portion	125,000	0
Other current liabilities	10,690	5,567
Total current liabilities	208,098	64,047
Senior secured notes, less current portion	0	125,000
Capital lease obligations, less current portion	1,335	4,139
Liability related to sale of future royalties	121,147	120,471
Deferred revenue, less current portion	68,941	76,911
Other long-term liabilities	10,672	14,721
Total liabilities	$ 410,193	$ 405,289
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized, no shares designated, issued or outstanding at September 30, 2015 or December 31, 2014	$ 0	$ 0
Common stock, $0.0001 par value, 300,000 authorized; 133,217 shares and 131,216 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	13	13
Capital in excess of par value	1,854,210	1,824,195
Accumulated other comprehensive loss	(1,821)	(1,567)
Accumulated deficit	(1,813,349)	(1,786,309)
Total stockholders' equity	39,053	36,332
Total liabilities and stockholders' equity	$ 449,246	$ 441,621